

Corporate Name: AGC Inc.
 President & CEO: Yoshinori Hirai
 (Code Number: 5201; TSE Prime Market)
 Contact: Kazumi Tamaki, Executive Officer, General Manager,
 Corporate Communications & Investor Relations
 (Tel: +81-3-3218-5603)

**Notice Regarding Revision to Full Year Consolidated Financial Forecasts
 for Fiscal Year Ending December 31, 2025**

AGC Inc. (the "Company") hereby announces that it has revised its full year consolidated financial forecasts for the fiscal year 2025, which were announced on February 7, 2025.

1. Revision to the consolidated financial forecasts

(1) Revision to the FY2025 consolidated financial forecasts

[January 1 through December 31, 2025]

(Unit: Millions of yen; %)

	Net sales	Operating profit	Profit before tax	Profit for the period	Profit for the period attributable to owners of the parent	Basic earnings per share (Yen)
Previous forecasts announced on February 7, 2025 (A)	2,150,000	150,000	135,000	98,000	80,000	377.43
Revised forecasts (B)	2,050,000	120,000	97,000	68,000	57,000	268.84
Change (B - A)	△100,000	△30,000	△38,000	△30,000	△23,000	△108.59
Change (%) (B - A)/A	△4.7	△20.0	△28.1	△30.6	△28.8	△28.8
(Reference) Actual results for FY2024	2,067,603	125,835	△50,050	△77,924	△94,042	△443.71

(2) Reasons for the revision of the consolidated financial forecasts

Net sales and operating profit are expected to be lower than the forecast due to several factors: the significant shortfall in sales volume caused by a production issue in the biopharmaceuticals CDMO business in the Life Science segment; the lower sales price of PVC in the Chemicals segment; and the shortfall in sales volume of semiconductor-related products in the Electronics segment.

Profit before tax, profit for the period, and profit for the period attributable to owners of the parent are also expected to be lower than forecast due to the aforementioned factors and the recognition of impairment losses resulting from the decision to proceed with structural reforms regarding the Boulder site and the Longmont site in Colorado, USA, as part of the biopharmaceuticals CDMO business.

The dividends forecast remains unchanged despite the revision of the financial forecast.

*The above forecasts were prepared based on the information available as of the day of this announcement. Actual results may differ from the forecast figures for various reasons.